Skip to Content
Merck
CN

SML4011

Sigma-Aldrich

BPTPE

≥98% (HPLC)

Synonym(s):

1,1-Bis(4-hydroxyphenyl)-2-phenyl-1-butene, 4,​4′-​(2-​Phenyl-​1-​butenylidene)​bis-phenol, 4,4′-(2-Phenylbut-1-ene-1,1-diyl)diphenol; triphenylethylene bisphenol

Sign Into View Organizational & Contract Pricing

Select a Size


About This Item

Empirical Formula (Hill Notation):
C22H20O2
CAS Number:
Molecular Weight:
316.39
MDL number:
UNSPSC Code:
51111800
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Quality Level

Assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

2-8°C

Biochem/physiol Actions

Potent partial estrogen agonist.



BPTPE, an angular estrogen, is a potent partial estrogen agonist. It induces cell cycle regulated genes that are like those activated by E2 in MCF7 cells. BPTPE exhibits delayed induction of unfolded protein response (UPR) and apoptosis in numerous breast cancer models.

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Regulatory Information

新产品
This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Balkees Abderrahman et al.
Molecular pharmacology, 98(4), 364-381 (2020-08-14)
Long-term estrogen deprivation (LTED) with tamoxifen (TAM) or aromatase inhibitors leads to endocrine-resistance, whereby physiologic levels of estrogen kill breast cancer (BC). Estrogen therapy is effective in treating patients with advanced BC after resistance to TAM and aromatase inhibitors develops.
I E Obiorah et al.
British journal of pharmacology, 171(17), 4062-4072 (2014-05-14)
Triphenylethylene (TPE)-like compounds were the first agents to be used in the treatment of metastatic breast cancer in postmenopausal women. Although structurally related to the anti-oestrogen, 4-hydroxytamoxifen, TPEs possess oestrogenic properties in fully oestrogenized breast cancer cells but do not

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service